PUBLIC COMPANY
save$PRMEPrime Medicine, Inc.
$PRME4.1900-1.87%Cambridge, MA, USupdated 14h ago
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
2Preclinical1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
- phase2A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)
- phase2A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
- —Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial
🐶 Hiring Signal
Where Prime Medicine, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaOncology 11
News
- Plug-and-play gene therapy: FDA executes on vision that’s been in the works for yearsFormer biologics boss Peter Marks had a vision. With the FDA’s latest draft guidance, it’s coming to fruition. Speaking with BioSpace, current CBER leader Karim Mikhail said the “adapted pathway” i…biospace · 15d ago
- FDA unveils guidance for ‘plug and play’ gene therapiesThe plan builds on recent FDA moves to speed "personalized" treatments by offering an approval framework for therapies benefiting different subsets of patients with the same disease.biopharma_dive · 19d ago
- STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATDBiotech companies are racing to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes, startup defections, arbitration, and a U.S.-China rivalry.stat · 3mo ago
Data sources
last refreshed 59m ago
Found something off?
comments(0)
5-min edit window · permanent after that